Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator

Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator

Background/Aims: Aspirin has been demonstrated to possess potent chemopreventive and anticancer effects on prostate cancer. However, the more detailed molecular mechanisms of aspirin to suppress prostate cancer cell invasion have not been clearly elucidated. Methods: Transwell assays were performed...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Chongjun Shi, Nini Zhang, Yang Feng, Jiewei Cao, Xuyi Chen, Bin Liu
Format:	Artykuł
Język:	English
Wydane:	Cell Physiol Biochem Press GmbH & Co KG 2017-03-01
Seria:	Cellular Physiology and Biochemistry
Hasła przedmiotowe:	Invasion Matrix metalloproteinase Nuclear factor-kappa B Prostate cancer Urokinase-type plasminogen activator
Dostęp online:	http://www.karger.com/Article/FullText/464434

Podobne zapisy

Inhibitory effects of wogonin on invasion by human oral cancer cells by decreasing the activity of matrix metalloproteinases and urokinase-plasminogen activator
od: Yung-Chuan Ho, i wsp.
Wydane: (2014-06-01)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin′s Lymphoma
od: Shirin Kouhpayeh, i wsp.
Wydane: (2017-01-01)

Specific inhibitors of urokinase plasminogen activator for treatment of cancers; In silico approach
od: Benjamin Talbot, i wsp.
Wydane: (2020-05-01)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
od: Koh, Angela S., i wsp.
Wydane: (2018)

Serum levels of urokinase-type plasminogen activator in healthy dogs and oncologic canine patients
od: Sofia C. Ramos, i wsp.
Wydane: (2017-08-01)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
od: Lampelj Maja, i wsp.
Wydane: (2015-12-01)

Urokinase-type plasminogen activator is a modulator of synaptic plasticity in the central nervous system: implications for neurorepair in the ischemic brain
od: Manuel Yepes
Wydane: (2020-01-01)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
od: Shengyuan Luo, i wsp.
Wydane: (2022-09-01)

Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge
od: Krzysztof Kowal,, i wsp.
Wydane: (2010-04-01)

Predicting Mortality in African Americans With Type 2 Diabetes Mellitus: Soluble Urokinase Plasminogen Activator Receptor, Coronary Artery Calcium, and High‐Sensitivity C‐Reactive Protein
od: Salim S. Hayek, i wsp.
Wydane: (2018-05-01)

The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets
od: Ashna A. Kumar, i wsp.
Wydane: (2022-01-01)

Cancer Progression Gene Expression Profiling Identifies the Urokinase Plasminogen Activator Receptor as a Biomarker of Metastasis in Cutaneous Squamous Cell Carcinoma
od: Elahe Minaei, i wsp.
Wydane: (2022-04-01)

QSAR modelling to predict structural features of certain sulfonamide as Urokinase-type Plasminogen Activator inhibitors
od: Rahul D. Jawarkar, i wsp.
Wydane: (2024-06-01)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
od: Nergiz Erkut, i wsp.
Wydane: (2016-05-01)

Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
od: Tetiana Yatsenko, i wsp.
Wydane: (2024-01-01)

Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer
od: Auxtine Micalet, i wsp.
Wydane: (2023-12-01)

Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19
od: Tetiana Yatsenko, i wsp.
Wydane: (2024-03-01)

Soluble urokinase plasminogen activator receptor and its complicated role in hemodialysis (HD) patients with Covid-19 infection
od: Ioannis Griveas, i wsp.
Wydane: (2021-07-01)

Monitoring of chemotherapy successfulness of Platina/Taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II
od: Dženita Ljuca, i wsp.
Wydane: (2007-05-01)

Predictive value of soluble urokinase-type plasminogen activator receptor in patients with severe acute pancreatitis
od: LI Yang, i wsp.
Wydane: (2022-02-01)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
od: Noboru Ichihara, i wsp.
Wydane: (2017-10-01)

Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor‐1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans
od: Michel T. Corban, i wsp.
Wydane: (2018-08-01)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
od: Ran Zhu, i wsp.
Wydane: (2022-08-01)

Can serum soluble urokinase plasminogen activator receptor be an effective biomarker in comparing the inflammatory response between laparoscopic and open appendectomy?
od: Basak Erginel, i wsp.
Wydane: (2023-06-01)

Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Induction by Etoposide in a Glioblastoma Cell Strain
od: Branko Brdar, i wsp.
Wydane: (2002-01-01)

Fibrinolysis regulation by platelets retaining plasminogen and tissue-type plasminogen activator on their surface
od: T. Grinenko, i wsp.
Wydane: (2019-12-01)

The unique invasiveness of glioblastoma and possible drug targets on extracellular matrix
od: Hatoum A, i wsp.
Wydane: (2019-02-01)

Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator
od: Mostafa Hamada, i wsp.
Wydane: (2024-05-01)

The Urokinase-Type Plasminogen Activator Contributes to cAMP-Induced Steroidogenesis in MA-10 Leydig Cells
od: Zoheir B. Demmouche, i wsp.
Wydane: (2022-07-01)

Urokinase vs Tissue-Type Plasminogen Activator for Thrombolytic Evacuation of Spontaneous Intracerebral Hemorrhage in Basal Ganglia
od: Yuqian Li, i wsp.
Wydane: (2017-08-01)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
od: Niaz Mahmood, i wsp.
Wydane: (2018-02-01)

Soluble urokinase-type plasminogen activator receptor as a biomarker of treatment response in childhood tuberculosis
od: Ery Olivianto, i wsp.
Wydane: (2019-01-01)

Febrile phase soluble urokinase plasminogen activator receptor and olfactomedin 4 as prognostic biomarkers for severe dengue in adults
od: Teo, Andrew, i wsp.
Wydane: (2024)

Clinical value of soluble urokinase-type plasminogen activator receptor in predicting sepsis-associated acute kidney injury
od: Wenwen Zhang, i wsp.
Wydane: (2024-12-01)

Soluble urokinase-type plasminogen activator receptor as a biomarker for focal segmental glomerulosclerosis; a retrospective analysis
od: Miguel Verdelho, i wsp.
Wydane: (2018-07-01)

Inhibition of Urokinase-Type Plasminogen Activator Expression by Macelignan in Porphyromonas gingivalis Supernatant-Induced Human Oral Epithelial Cells
od: YANTI
Wydane: (2010-03-01)

Inhibition of Urokinase-Type Plasminogen Activator Expression by Macelignan in Porphyromonas gingivalis Supernatant-Induced Human Oral Epithelial Cells
od: YANTI
Wydane: (2010-03-01)

Soluble urokinase plasminogen activator receptor: a novel biomarker of pediatric community-acquired and hospitalacquired pneumonia
od: Muhammad Said El-Mekkawy, i wsp.
Wydane: (2022-02-01)

Proteomics-Based Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated With Incident Heart Failure Risk
od: Adithya K. Yadalam, MD, MSc, i wsp.
Wydane: (2025-01-01)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
od: Angela S. Koh, i wsp.
Wydane: (2017-11-01)